LIFE - CIK 0001339970
aTYR PHARMA INC trades as LIFE and has a market capitalization of $1.67 B, making it the #2240 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $190.00K, down 19.1% from the prior year and net income of -$74.12M. This page tracks aTYR PHARMA INC through 720 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 6 fiscal years aTYR PHARMA INC's revenue declined from $422.00K to $190.00K, a compound annual decline rate of 12.5%. Net profit margin compressed from -3844.5% to -39009.5% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-15 |
| Major company event | 8-K | 2026-05-15 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update | aTyr Pharma
aTyr Pharma to Participate in Upcoming Investor Conferences | aTyr Pharma
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting | aTyr Pharma
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update | aTyr Pharma
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | aTyr Pharma
The largest companies sharing aTYR PHARMA INC's SEC industry classification (biological products, (no diagnostic substances)).
aTYR PHARMA INC (LIFE) has a market capitalization of $1.67 B as of 2026-06-10, ranking #2240 among US-listed companies.
aTYR PHARMA INC reported revenue of $190.00K for fiscal year 2025, a decrease of 19.1% year over year.
In its latest fiscal year aTYR PHARMA INC reported a net loss of $74.12M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.